Qualitative and Quantitative Heterogeniety in Acquiring Resistance to EGFR Kinase Inhibitors in Lung Cancer

被引：0
|
作者：
Suda, Kenichi [1 ]
Murakami, Isao [2 ]
Sakai, Kazuko [3 ]
Mizuuchi, Hiroshi [1 ]
Sato, Katsuaki [1 ]
Tomizawa, Kenji [1 ]
Nishio, Kazuto [3 ]
Mitsudomi, Tetsuya [1 ]
机构：
[1] Kinki Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Japan
[2] Higashi Hiroshima Med Ctr, Dept Resp Med, Higashihiroshima, Japan
[3] Kinki Univ, Fac Med, Dept Genome Biol, Osaka, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
T790M mutation; Molecular targeted therapy; EGFR mutation; lung adenocarcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ORAL42.02
引用
收藏
页码：S256 / S257
页数：2
相关论文
共 50 条
  • [1] HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
    Yano, Seiji
    Wang, Wei
    Li, Qi
    Yamada, Tadaaki
    Takeuchi, Shinji
    Matsumoto, Kunio
    Nishioka, Yasuhiko
    Sone, Saburo
    CURRENT SIGNAL TRANSDUCTION THERAPY, 2011, 6 (02) : 228 - 233
  • [2] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Soh, Junichi
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
  • [3] V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors
    Matsushima, Satsuki
    Ohtsuka, Kouki
    Ohnishi, Hiroaki
    Fujiwara, Masachika
    Nakamura, Hiroyuki
    Morii, Takeshi
    Kishino, Tomonori
    Goto, Hajime
    Watanabe, Takashi
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : 1377 - 1384
  • [4] Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
    Suda, Kenichi
    Rivard, Christopher J.
    Mitsudomi, Tetsuya
    Hirsch, Fred R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (09) : 779 - 786
  • [5] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    Wang, Jun
    Wang, Baocheng
    Chu, Huili
    Yao, Yunfeng
    ONCOTARGETS AND THERAPY, 2016, 9 : 3711 - 3726
  • [6] EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance
    Remon, Jordi
    Majem, Margarita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (06) : 445 - 448
  • [7] Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer
    Suda, Kenichi
    Rozeboom, Leslie
    Rivard, Christopher
    Yu, Hui
    Melnick, Mary Ann
    Hinz, Trista
    Ellison, Kim
    Chan, Daniel
    Politi, Katerina
    Heasley, Lynn
    Mitsudomi, Tetsuya
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S433 - S434
  • [8] The influence of pemetrexed on subsequent treatment with EGFR-tyrosine kinase inhibitors in lung cancer
    Kobayashi, Yoshihisa
    Tomida, Shuta
    Sesumi, Yuichi
    Tomizawa, Kenji
    Mitsudomi, Tetsuya
    CANCER SCIENCE, 2018, 109 : 916 - 916
  • [9] Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
    Yano, Seiji
    Yamada, Tadaaki
    Takeuchi, Shinji
    Tachibana, Keisei
    Minami, Yuko
    Yatabe, Yasushi
    Mitsudomi, Tetsuya
    Tanaka, Hidenori
    Kimura, Tatsuo
    Kudoh, Shinzoh
    Nokihara, Hiroshi
    Ohe, Yuichiro
    Yokota, Jun
    Uramoto, Hidetaka
    Yasumoto, Kosei
    Kiura, Katsuyuki
    Higashiyama, Masahiko
    Oda, Makoto
    Saito, Haruhiro
    Yoshida, Junji
    Kondoh, Kazuya
    Noguchi, Masayuki
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2011 - 2017
  • [10] Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
    Dagogo-Jack, Ibiayi
    Engelman, Jeffrey A.
    Shaw, Alice T.
    ANNUAL REVIEW OF CANCER BIOLOGY, VOL 1, 2017, 1 : 257 - 274
12345